A theoretical model for prescription of the patient-specific therapeutic activity for radioiodine therapy of Graves' disease.
作者： F Di Martino , A C Traino , A B Brill , M G Stabin , M Lazzeri
DOI: 10.1088/0031-9155/47/9/305
关键词:
摘要: A fundamental function of the thyroid is to extract iodine from blood, synthesize it into hormones, and release circulation under feedback control by pituitary-secreted hormones. This capability thyroid, termed as functionality, can in principle be related severity hyperthyroidism individual patients. In this paper uptake 131I following administration therapy for Graves' disease has been theoretically studied. The kinetics blood have evaluated using a two-compartment model. simplified model appears adequate dosimetry purposes allows one correlate levels increased functionality (hyperthyroidism) with clinically measurable kinetic parameters. An expression derived rate change mass therapy; same form an empirical relationship described earlier work. method presented calculation amount radioiodine activity administered patients order achieve desired final gland. based on measurements after 'low-activity' (1850 kBq) tracer treatment planning.
harvard.edu
sci-hub.se 参考文章(10)
Robert A. Nordyke, Fred I. Gilbert, Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. The Journal of Nuclear Medicine. ,vol. 32, pp. 411- 416 ,(1991)
A C Traino, F Di Martino, M Lazzeri, M G Stabin, Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism Physics in Medicine and Biology. ,vol. 45, pp. 121- 129 ,(2000) , 10.1088/0031-9155/45/1/309
H. PETERS, C. FISCHER, U. BOGNER, C. REINERS, H. SCHLEUSENER, Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. European Journal of Clinical Investigation. ,vol. 26, pp. 59- 63 ,(1996) , 10.1046/J.1365-2362.1996.98243.X
H. PETERS, C. FISCHER, U. BOGNER, C. REINERS, H. SCHLEUSENER, Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. European Journal of Clinical Investigation. ,vol. 25, pp. 186- 193 ,(1995) , 10.1111/J.1365-2362.1995.TB01547.X
LASZLO BAJNOK, EMESE MEZOSI, ENDRE NAGY, JENO SZABO, ILONA SZTOJKA, JOZSEF VARGA, LASZLO GALUSKA, ANDRAS LEOVEY, Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary? Thyroid. ,vol. 9, pp. 865- 869 ,(1999) , 10.1089/THY.1999.9.865
Pat B. Zanzonico, Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. The Journal of Nuclear Medicine. ,vol. 41, pp. 297- 308 ,(2000)
M G. Stabin, D A. Weber, J A. Siegel, S R. Thomas, J B. Stubbs, R W. Howell, J S. Robertson, A B. Brill, B W. Wessels, Darrell R. Fisher, M T. Hays, K F. Koral, MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. The Journal of Nuclear Medicine. ,vol. 40, ,(1999)
A.C. Traino, F. Di Martino, M. Lazzeri, M.G. Stabin, Study of the correlation between administered activity and radiation committed dose to the thyroid in 131I therapy of Graves' disease. Radiation Protection Dosimetry. ,vol. 95, pp. 117- 124 ,(2001) , 10.1093/OXFORDJOURNALS.RPD.A006531
A Bockisch, H J Biersack, R Derwanz, T Jamitzky, Optimized dose planning of radioiodine therapy of benign thyroidal diseases. The Journal of Nuclear Medicine. ,vol. 34, pp. 1632- 1638 ,(1993)
F. Bogazzi, M. G. Stabin, A. Pinchera, F. Lippi, A. Campomori, E. Martino, F. Di Martino, Marco Ferdeghini, M. Lazzeri, B. Alberti, A. C. Traino, P. Vitti, L. Bartalena, A mathematical model of thyroid mass reduction after radioiodine therapy of Graves’ disease ,vol. 16, pp. 127- 136 ,(2001)